 3. Have measurable disease according to RECIST or detectable disease by 1 CA-125 at least twice the ULN within 14 days prior to registration for protocol therapy; 2 Ascites andor pleural effusion attributed to tumor; 3 solid andor cystic abnormalities on radiographic imaging that do not meet RECIST definitions for target lesions. Radiographic assessments must be obtained within 28 days prior to registration for protocol therapy. 